Post by
Carolpeters24 on Jul 26, 2022 10:31am
ValiRx and TheoremRx - VAL201 - US$61M plus royalties
Dr Ken Sorensen, Chairman of TheoremRx We are delighted out latest fundraising od $250m has brought in multiple financial institutions as we now move forward with our strategic plans.
Dr Ken Sorensen, Chairman of TheoremRx stated: "We have appreciated the work carried out so far, and we will now move forward with VAL201 as it is an important part of our pipeline of new projects."
First payments to ValiRx are expected on or before the end of July.
The proposed sub-licence of VAL201 to TheoremRx Inc. VAL201's primary indication is for prostate cancer, with potential further research & development in breast and ovarian cancer.
The potential value of the deal would be in excess of US$61M plus royalties for the first cancer indication alone. Each oncology indication successfully developed to by TheoremRx will generate up to $37.5M of additional value to ValiRx. The proposed deal structure comprises payments on signature of the Licence Agreement plus fees and near-term milestones totalling US$2.2M before the end of 2023, milestones on further clinical and commercial development events, and royalties. The first payments are expected by the end of July 2022.
https://www.fidelity.co.uk/shares/stock-market-news/company-news/
Comment by
Oldbaldy on Oct 22, 2023 8:47am
So is there any truth in this....?